学科与关键词
关键词
PD-L1 inhibitorAnlotinibES-SCLC
- EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)Cheng, Y.; Liu, Y.; Zhang, W.; Wu, L.; Zhou, C.; Wang, D.; Xia, B.; Bi, M.; Fu, X.; Li, C.; Chen, G.; Lv, D.; Zhao, Y.; Huang, J.; Li, M.; Yi, T.; Huang, X.; Yang, R.; Chen, Z.; Wang, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.Wang, Wei; Lin, Shuimiao; Wang, Rong; Wu, DehuaGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.
- Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial.Cheng, Ying; Wang, Jie; Zhou, Caicun; Yao, Wenxiu; Wang, Qiming; Min, Xuhong; Chen, Gongyan; Xu, Xingxiang; Li, Xingya; Xu, Fei; Fang, Yong; Yang, Runxiang; Yu, Guohua; Gong, Youling; Zhao, Jun; Fan, Yun; Liu, Quan; Cao, Lejie; Yao, Yu; Liu, Yunpeng; Li, Xiaoling; Wu, Jingxun; He, Zhiyong; Lu, Kaihua; Jiang, Liyan; Yu, Huiqing; Hu, Chengping; Zhao, Wenhua; Zhao, Jian; Wu, Gang; Huang, Dingzhi; Chen, Chengshui; Ding, Cuimin; Zhang, Baihong; Wang, Xiuwen; Luo, Hui; Li, Baolan; Zhang, BenAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.
